The International Trade Commission is a hot forum for patent disputes, but it’s almost never used by pharmaceutical companies, whose IP cases typically involve specialized fights between brand-name and generic drug makers.

That may be changing. In a novel strategy to beat back generic competition to its blockbuster cancer drug Gemzar, Eli Lilly and Co. has turned to the ITC.